Search for: "Lisa Larrimore Ouellette" Results 101 - 120 of 122
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
How are COVID-19 vaccine developers and regulators responding to variants?
25 Mar 2021, 1:24 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What can policymakers learn from the disastrously slow COVID-19 vaccine rollout?
12 Jan 2021, 9:04 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How will the FDA’s new COVID-19 vaccine guidance affect development efforts?
10 Jul 2020, 8:59 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PricePolicymakers are expectantly awaiting the development [read post]
Written Description - http://writtendescription.blogspot.com/
Sapna Kumar: The Fate Of "Innovation Nationalism" In The Age of Trump
9 Mar 2018, 12:54 pm by Camilla Alexandra Hrdy
To give one example, in their recent article, Bayh-Dole Without Borders, Lisa Larrimore Ouellette [read post]
Written Description - http://writtendescription.blogspot.com/
Guest Post: Assessing Responses to the PTO’s 2021 Patent Eligibility Study
1 Feb 2022, 6:48 am by Jason Rantanen
Durvasula, Lisa Larrimore Ouellette, and Heidi L. Williams. [read post]
Patently-O - https://patentlyo.com
What are the challenges in developing information around mixing-and-matching COVID-19 vaccines and therapies?
21 Jan 2022, 8:35 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceThe FDA has now authorized three vaccines and several [read post]
Written Description - http://writtendescription.blogspot.com/
How can health regulators maintain public trust when facing scientific uncertainty?
24 Jun 2020, 5:36 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Remdesivir Part II: Allocating Access
19 May 2020, 3:30 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives [read post]
Written Description - http://writtendescription.blogspot.com/
Regulatory Responses to N95 Respirator Shortages
21 Apr 2020, 2:09 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted [read post]
Written Description - http://writtendescription.blogspot.com/
How can innovation and regulatory policy accomplish robust COVID-19 testing?
15 Apr 2020, 8:14 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that [read post]
Written Description - http://writtendescription.blogspot.com/
Molnupiravir may become the first COVID-19 pill. What took so long?
5 Nov 2021, 8:20 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?
25 Aug 2020, 4:50 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How can the government improve access to COVID-19 preventatives and treatments for low-income Americans?
18 Jun 2020, 1:23 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsIn the United States, one of the [read post]
Written Description - http://writtendescription.blogspot.com/
What does it mean that Oracle is partnering with the Trump administration to study unproven COVID-19 drugs?
30 Mar 2020, 8:40 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOne of the dizzying stream [read post]
Written Description - http://writtendescription.blogspot.com/
What does ending the COVID-19 pandemic mean from a legal perspective?
8 Jun 2022, 5:23 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Census of Law Professor Twitter Users Version 3.1
6 Feb 2015, 6:00 am by Bridget Crawford
Lisa Larrimore Ouellette (Stanford) (@PatentScholar) has created a Twitter list that makes it easier [read post]
The Faculty Lounge - https://www.thefacultylounge.org/
Dow v. Nova: “Nautilus changed the law of indefiniteness”
1 Sep 2015, 3:52 am by Jason Rantanen
Lisa Larrimore Ouellette discusses the decision on the Written Description blog as well. [read post]
Patently-O - https://patentlyo.com
First Steps After SAS Institute
27 Apr 2018, 7:20 am by Dennis Crouch
indebted to my co-panelists Mark Lemley, David O’Brien, and Stefani Shanberg and to our moderator Lisa [read post]
Patently-O - https://patentlyo.com
Local Commercialization Incentives
11 Mar 2014, 7:56 pm by Guest Blogger
abstract_id=1755091[33] Lisa Larrimore Ouellette makes a similar argument about the benefits of local [read post]
Balkinization - http://balkin.blogspot.com/
The Initial Interest Confusion Doctrine Refuses to Die
15 Nov 2025, 10:27 am by Eric Goldman
rdquo; mark is strong based on Kyjen’s high prominence in search results (sadly, no citation to Lisa [read post]
Technology & Marketing Law Blog - http://blog.ericgoldman.org/